PortfoliosLab logoPortfoliosLab logo
ISIN
US29772L1089
CUSIP
29772L108
IPO Date
Nov 13, 2018

Highlights

Market Cap
$1.03B
Enterprise Value
$1.04B
EPS (TTM)
-$0.05
Total Revenue (TTM)
$86.93M
Gross Profit (TTM)
$47.61M
EBITDA (TTM)
$5.70M
Year Range
$13.09 - $35.66
Target Price
$25.00
ROA (TTM)
-1.51%
ROE (TTM)
-4.82%

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

ETON Performance Chart

Eton Pharmaceuticals Inc (ETON) is up 93.5% since the beginning of the year. At $33 per share, ETON is trading 8.2% below its 52-week high of $36. Investors who bought $1,000 worth of ETON shares 5 years ago would now be looking at an investment worth $5,536.


Loading charts...

S&P 500 Index

Returns By Period

Eton Pharmaceuticals Inc (ETON) has returned 93.49% so far this year and 141.12% over the past 12 months.


Eton Pharmaceuticals Inc

1D
0.74%
1M
0.40%
YTD
93.49%
6M
97.47%
1Y
141.12%
3Y*
102.17%
5Y*
40.81%
10Y*

Benchmark (S&P 500 Index)

1D
-0.37%
1M
-0.01%
YTD
9.16%
6M
8.64%
1Y
25.22%
3Y*
19.78%
5Y*
11.99%
10Y*
13.88%
*Multi-year figures are annualized to reflect compound growth (CAGR)

ETON Monthly Returns History

Based on dividend-adjusted daily data since Nov 13, 2018, ETON's average daily return is +0.17%, while the average monthly return is +3.30%. At this rate, an investment would double in approximately 1.8 years.

Historically, 51% of months were positive and 49% were negative. The best month was Nov 2024 with a return of +59.7%, while the worst month was Nov 2021 at -32.3%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 3 months.

On a daily basis, ETON closed higher 49% of trading days. The best single day was Aug 11, 2023 with a return of +38.1%, while the worst single day was Mar 16, 2020 at -20.5%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026-11.24%13.19%45.26%-2.27%26.24%7.45%93.49%
202532.73%-11.20%-17.32%29.82%12.11%-24.56%-0.63%22.25%25.53%-17.12%-10.33%4.71%26.95%
20246.62%-4.71%-15.73%-6.67%1.43%-7.32%9.42%27.78%30.43%41.17%59.74%-1.55%204.11%
202323.40%7.18%3.22%-5.71%9.09%-11.87%-19.20%59.57%-7.33%1.20%-16.11%23.73%55.32%
2022-13.75%1.62%15.96%-19.04%-13.88%-13.82%2.29%-15.67%-7.08%21.43%18.43%-6.62%-34.27%
20219.72%-11.32%-7.46%18.58%-18.66%-12.75%-16.56%2.53%-4.36%14.29%-32.29%10.00%-47.23%

Benchmark Metrics

Eton Pharmaceuticals Inc has an annualized alpha of 33.83%, beta of 0.81, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since November 13, 2018.

  • This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (88.22%) than losses (43.46%) - typical of diversified or defensive assets.
  • R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
33.83%
Beta
0.81
0.06
Upside Capture
88.22%
Downside Capture
43.46%

Return for Risk

Risk / Return Rank

ETON ranks 89 for risk / return — in the top 89% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.


ETON Risk / Return Rank: 8989
Overall Rank
ETON Sharpe Ratio Rank: 9393
Sharpe Ratio Rank
ETON Sortino Ratio Rank: 9090
Sortino Ratio Rank
ETON Omega Ratio Rank: 9090
Omega Ratio Rank
ETON Calmar Ratio Rank: 8888
Calmar Ratio Rank
ETON Martin Ratio Rank: 8484
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Eton Pharmaceuticals Inc (ETON) and compare them to S&P 500 Index.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


ETONBenchmarkDifference
Sharpe ratioReturn per unit of total volatility

+0.58

Sortino ratioReturn per unit of downside risk

+0.42

Omega ratioGain probability vs. loss probability

1.41

1.37

+0.05

Calmar ratioReturn relative to maximum drawdown

3.93

2.78

+1.14

Martin ratioReturn relative to average drawdown

8.07

12.44

-4.37

Dividends

Dividend History


Eton Pharmaceuticals Inc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the Eton Pharmaceuticals Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Eton Pharmaceuticals Inc was 79.94%, occurring on Oct 20, 2022. Recovery took 519 trading sessions.

The current Eton Pharmaceuticals Inc drawdown is 6.51%.


Related event

Drawdown

Fall

Recovery

Underwater

Bear market2022
-79.94%Oct 2022
1y 8mo2y 25d
3y 8moFeb 2021 - Nov 2024
COVID crash2020
-67.13%Mar 2020
8mo 11d6mo 4d
1y 2moJul 2019 - Sep 2020
2025 selloff2025
-37.15%Apr 2025
2mo 1d1mo 7d
3mo 8dFeb 2025 - May 2025
2026 bear market2026
-36.17%Feb 2026
4mo 8d1mo 16d
5mo 24dSep 2025 - Mar 2026
2025 selloff2025
-33.33%Jun 2025
1mo 3d3mo 3d
4mo 6dMay 2025 - Sep 2025

Drawdown Indicators


ETONBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-79.94%

-56.78%

-23.16%

Max Drawdown (1Y)

Largest decline over 1 year

-36.17%

-9.10%

-27.07%

Max Drawdown (3Y)

Largest decline over 3 years

-45.65%

-18.90%

-26.75%

Max Drawdown (5Y)

Largest decline over 5 years

-69.35%

-25.43%

-43.92%

Max Drawdown (10Y)

Largest decline over 10 years

-33.92%

Current Drawdown

Current decline from peak

-6.51%

-1.80%

-4.71%

Average Drawdown

Average peak-to-trough decline

-37.50%

-10.71%

-26.79%

Ulcer Index

Depth and duration of drawdowns from previous peaks

17.56%

2.03%

+15.53%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Eton Pharmaceuticals Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Eton Pharmaceuticals Inc is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for ETON relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, ETON has a P/S ratio of 10.6. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for ETON in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, ETON has a P/B value of 33.7. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with ETON

Add Eton Pharmaceuticals Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with ETON